Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safety profile, supporting plans for late-stage testing. RAP-219 also shows potential for treating focal epilepsy, with analysts estimating peak sales could reach $1 billion. The stock responded with increased trading volume and a price rise, reflecting optimism about the drug's commercial prospects.
Raymond James' raised target for Rapport Therapeutics provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 21, 2026 02:12 WIB: out of 150 priced US health-sector stocks, 133 rose and 16 fell. Notable movers include DFTX (Definium Therapeutics Inc.) up 7.19% at USD 35.34 with a typical hold time of 7 days, DVA (Davita Inc) down 6.99% at USD 173.93 with 24% sell and 76% buy order activity and a typical hold time of 115 days, and TNGX (Tango Therapeutics Inc.) up 6.97% at USD 25.17 with a typical hold time of 6 days.
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
Brunello Cucinelli, an Italian luxury fashion company, raised its 2026 outlook following stronger-than-expected third-quarter sales. Citigroup maintains a Buy rating on the stock, which trades around $9.43 with a market cap of approximately $6.41 bil...
Dime Community Bancshares reported Q3 2026 earnings per share of $0.91, surpassing analyst estimates of $0.86, and revenue of $135.30 million, exceeding expectations. The company showed a 17.1% year-over-year revenue increase, highlighting robust fin...
